Skip to main content
Abdeckung

All News Items

 

Berlin goes USA

21.11.2024 / Strengthening transatlantic economic relations: Berlin delegation trip to the USA - with a focus on life science and health … more

Max Delbrück Center signs licence agreement with Kite, a Gilead Company, for Sleeping Beauty Transposon System

20.11.2024 / Supported by its technology transfer partner Ascenion, Max Delbrück Center has entered into a licensing agreement with Kite providing the company with non-exclusive rights to use the transposon system for the genetic engineering of T cells. … more

Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024

14.11.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 million or € 1.12 per share. … more

Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225

13.11.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix totaling up to € 20 million within approximately two years, as well as access to a higher availability of Ac-225. … more

Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply

08.10.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its GMP grade non-carrier added Lutetium-177 chloride (n.c.a. Lu-177) for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers. … more

Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register

02.10.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pentixapharm AG became legally effective. All shares in Pentixapharm AG held by Eckert & Ziegler have thus been legally transferred from Eckert & Ziegler SE to Pentixapharm Holding AG. … more

OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease

27.09.2024 / Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025 … more

Einladung: Zukünfte der Künstlichen Intelligenz – Szenarien für die künftige Arbeitswelt

09.09.2024 / Keynote im Rahmen der Jahreskonferenz des Bundesverbands Deutscher Innovations-, Technologie- und Gründerzentren e.V. (BVIZ) … more

A new drug target for psychiatric disorders

05.09.2024 / Misha Kudryashev’s lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia. Published in “The EMBO Journal,” the study points to a potentially new target for therapeutics. … more

New in Berlin: tumor immunologist Johannes Huppa

02.09.2024 / Johannes Huppa has taken up the professorship for tumor immunology at Charité – Universitätsmedizin Berlin as of September 1. The T-cell receptor expert will also conduct research at the Max Delbrück Center in Berlin-Buch and the German Consortium for Translational Cancer Research (DKTK). … more

New clues on how the heart makes arteries

30.08.2024 / A team in the labs of Holger Gerhardt and Norbert Hübner at the Max Delbrück Center has elucidated how new arteries form, potentially helping to improve therapies aimed at regenerating heart muscle after a heart attack or stroke. The research was published in “Circulation Research.” … more

Surprising mechanism of lupus kidney damage identified

15.08.2024 / A team led by Charité – Universitätsmedizin Berlin, German Rheumatology Research Center and the Max Delbrück Center have defined key cells behind severe kidney damage in lupus. The research, published in “Nature,” can inform future antibody therapies. … more

Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study

13.08.2024 / Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study. The contract covers the supply of the entire European patient base from the state-of-the-art facility in Berlin. In addition, Eckert & Ziegler will also be a provider of the crucial starting material in the form of their high-purity, non-carrier added GMP-grade Lutetium-177 (Lu-177). … more

Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area

05.08.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide generator GalliaPharm®. The generator was first launched in 2014 and is today approved in 17 European countries and many other key international markets. With the EC approval, an additional 14 countries in the European Economic Area (EEA) will gain access to GalliaPharm®, once national approval procedures have been completed. Consequently, it will soon be the first generator for the production of Gallium-68 commercially available in the entire EEA. … more

A vast viral world in wastewater

19.07.2024 / Deep metagenomic sequencing of wastewater in Berlin over 17 months shows this technique could help forecast disease outbreaks and monitor the spread of human pathogens. It can also reveal thousands of novel viruses, according to a study by the Landthaler lab published in “Environment International.” … more

The Imaging Innovation Center hits a milestone

12.07.2024 / The Max Delbrück Center, Berlin, celebrates its new, innovative research building with a “topping-out ceremony.” The Imaging Innovation Center, designed by the architectural firm heinlewischer, will host researchers specializing in imaging and analysis alongside data experts under one roof starting in 2026. … more

Mechanism of phosphorylation in TREK channels offers therapeutic potential

11.07.2024 / A team led by Prof. Dr. Han Sun from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has elucidated an important mechanism in the function of TREK channels at an atomic level. The results, published in the journal "Nature Communications," could facilitate the development of therapeutics for diseases such as ischemia, epilepsy, and depression. … more

Giant with a Ceramic Heart

04.07.2024 / A new NMR spectrometer has been in operation at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) since the end of May. What makes it special is that it is based on a new type of ceramic high-temperature superconductor. Peter Schmieder, head of the NMR technology platform at the FMP, explains the technology behind it and the capabilities of the new device. … more

Pentixapharm Acquires Target Discovery Business of Glycotope

03.07.2024 / Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery business of Berlin-based Glycotope GmbH. … more

Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler

01.07.2024 / Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a broad range of malignancies, announced today that the General Shareholder Meeting of Pentixapharm resolved the appointment of the distinguished endocrinologist Prof. Dr. med. Marcus Quinkler to the Company's Supervisory Board. The assignment will become effective with the registration of the split-off of Pentixapharm AG from Eckert & Ziegler SE in the commercial register. … more

Multiple myeloma: Early detection of aggressive tumors

28.06.2024 / Berlin researchers and their partners describe how aggressive variants of multiple myeloma can be detected early. Their comprehensive study in “Nature Cancer” shows how changes in genetic material affect the protein profile of the tumor cells, and thus the mechanisms involved in the disease. … more

Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG

27.06.2024 / The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year. … more

3D maps of diseased tissues at subcellular precision

26.06.2024 / An open-source platform developed by researchers in Nikolaus Rajewsky’s lab at the Max Delbrück Center creates molecular maps from patient tissue samples with subcellular precision, enabling detailed study and potentially enhancing routine clinical pathology. The study was published in “Cell.” … more

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism

25.06.2024 / Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registration study with its radiopharmaceutical diagnostic Ga68-PentixaFor in Primary Aldosteronism (PA). PA is an adrenal gland disorder also known as Conn’s syndrome and the most frequent cause of secondary hypertension (high blood pressure). … more

Novel Cancer Therapeutic from FMP Research Enters Clinical Phase

21.06.2024 / Groundbreaking innovations by researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) provided the basis for the development of an antibody-drug conjugate (ADC) by the company Tubulis, which is now being used in a Phase I/IIa trial in tumour patients. Thanks to an innovative linker chemistry known as P5 technology, the active substance is delivered safely to its target and can also develop its effect over a long period of time. The beginning of a clinical trial just a few years after the discovery of the P5 technology is a major achievement that demonstrates the potential for applied research in an academic research institute. … more

Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility

20.06.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”), announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated yesterday with an official ceremony featuring Czech Prime Minister Petr Fiala, marks the culmination of a longstanding partnership between Eckert & Ziegler and UJF. The facility is now close to operational readiness, and after additional testing, commercial production is slated to commence at the beginning of Q3/2024. … more

Talk im Cube: Building the bridge from preclinical to clinical studies

13.06.2024 / Join us for the next edition of Talk im Cube … more

Eckert & Ziegler receives “Best Managed Companies Award”

24.05.2024 / Eckert & Ziegler SE (ISIN DE0005659700) was honored with the “Best Managed Companies Award” at an award ceremony in Frankfurt am Main on May 23, 2024. With this award, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Federation of German Industries (Bundesverband der Deutschen Industrie e.V.) recognize outstandingly managed medium-sized companies. … more

€700,000 boost for preeclampsia research

23.05.2024 / Preeclampsia is one of the most common pregnancy-related complications. Florian Herse of the Max Delbrück Center and Martin Gauster of the Medical University of Graz are studying the role that Hofbauer cells play in the disorder. They have been awarded a D-A-CH grant totaling €700,000 for their research. … more

Captain T Cell secures seed financing round

22.05.2024 / Captain T Cell, a spin-off from the Max Delbrück Center, raised €8.5 million in startup funding. The startup focuses on developing T cells to target solid tumors. The funds are intended to move a new generation of T cell therapies towards the clinic. … more

Berlin-Buch goes BIO International Convention

21.05.2024 / The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. Campus Berlin-Buch GmbH is attending this year's event in San Diego from June 3-6. … more

Talk im Cube: Sustainable Practices in Life Sciences - A Panel Discussion (in English)

16.05.2024 / Don't miss this opportunity to engage with experts as we chart a path towards a more sustainable future. … more

EU-OPENSCREEN ERIC Launches New EU-Funded Project IMPULSE

29.04.2024 / EU-OPENSCREEN ERIC proudly announces the launch of its latest EU-funded Horizon Europe project, IMPULSE, after a two-day kick-off event held earlier this month. … more

From cell biology to CRISPR/Cas – new knowledge for schools

15.04.2024 / The Life Science Learning Lab at the Berlin-Buch research campus offers both school students and teachers the opportunity to immerse themselves in science. This year, the facility celebrates its 25th anniversary … more

ERC grants Berlin scientists €2.5 million each

11.04.2024 / Neuroscientists Gary Lewin and James Poulet at the Max Delbrück Center for Molecular Medicine have won highly coveted and competitive ERC Advanced Grants to study pain and the neural mechanisms that underlie temperature perception. … more

The Protein Expert

09.04.2024 / Prof. Dr. Fan Liu from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has recently received several awards for her contributions to the field of cross-linking mass spectrometry. The scientist is dedicated to better understanding the interactions between proteins at the cellular level. Additionally, she is developing methods and standards to refine this complex and indispensable technology for many research questions, making it more broadly applicable. … more

Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023

22.03.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26. … more

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

21.03.2024 / Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment of prostate cancer as well as eye and brain tumors, obtained the MDR certificate for its proprietary prostate seeds from DEKRA Certification B.V. as one of the first companies in its market. This important milestone guarantees a high level of patient safety and the long-term availability of the seeds within the EU. … more

Eckert & Ziegler Completes Change of Legal Form to SE

19.03.2024 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today completed its change of legal form to a Societas Europaea (SE) with entry in the company's commercial register and will in future operate as Eckert & Ziegler SE. … more